Nirmatrelvir/ritonavir treatment for COVID-19: an economic value systematic literature review
While economic evaluations were heterogeneous in terms of modeling approach, population, treatments, and context, these findings indicate that NMV/r has economic value for patients with mild-to-moderate COVID-19 with a high risk of progression to severe disease. Significant changes to the burden of COVID-19 due to the evolution of COVID-19 variants and new vaccination strategies, may warrant updates models.
Authors
- Nhu-y Phan (ORCID: https://orcid.org/0000-0002-3603-1736)
- Tendai Mugwagwa (ORCID: https://orcid.org/0000-0001-7515-8548)
- José S Marcano Belisario (ORCID: https://orcid.org/0000-0002-3372-2996)
- Louise Hartley (ORCID: https://orcid.org/0000-0001-5251-2321)
Institutions
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- RTI Health Solutions (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1080/13696998.2025.2579407
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 0.00